Linked Article: Prens et al. Br J Dermatol 2021; 185:177–184. Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease, with multiple systemic comorbidities1 Treatment challenging and adalimumab [tumour necrosis factor (TNF)-α monoclonal antibody] the only licensed therapy. It effective in approximately 50% of patients, based on Suppurativa Clinical Response results from phase III ...